Ezetimibe and reactive oxygen species

Current Vascular Pharmacology

Volumn 9, Issue 1, 2011, Pages 109-120

  Yamaoka Tojo, Minako ^a   Tojo, Taiki ^b   Takahira, Naonobu ^a   Masuda, Takashi ^a   Izumi, Tohru ^b  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Cholesterol; Dyslipidemia; Inflammation; Reactive oxygen species

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; EZETIMIBE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; N(G),N(G) DIMETHYLARGININE; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; TRIACYLGLYCEROL;

ADD ON THERAPY; ARTICLE; ATHEROSCLEROSIS; DRUG BINDING; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIUM; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPID OXIDATION; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; VASCULARIZATION;

ANIMALS; ATHEROSCLEROSIS; AZETIDINES; CHOLESTEROL, LDL; HUMANS; HYPERCHOLESTEROLEMIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 78650963108     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111793744652     Document Type: Article

References (147)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508-19.
3. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8: 802-15.
4. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009; 27: 165-97.
5. Homma Y. Predictors of atherosclerosis. J Atheroscler Thromb 2004; 11: 265-70.
6. Andrews HE, Bruckdorfer KR, Dunn RC, Jacobs M. Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature 1987; 327: 237-9.
7. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4.
8. Vasconcelos EM, Degasperi GR, de Oliveira HC, Vercesi AE, de Faria EC, Castilho LN. Reactive oxygen species generation in peripheral blood monocytes and oxidized LDL are increased in hyperlipidemic patients. Clin Biochem 2009; 42: 1222-7.
9. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173: 1-12.
10. Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008; 101: 483-5.
11. Miura S, Saku K. Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern Med 2008; 47: 1165-70.
12. Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol lowering and ezetimibe. N Engl J Med 2008; 358: 1507-8.
13. Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Canada. N Engl J Med 2008; 358: 1819-28.
14. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43.
15. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008; 358: 1504-7.
16. Rossebo AB, Pedersen TR, Allen C, et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 2007; 99: 970-3.
17. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int (Suppl) 2003; S207-10.
18. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin vs. simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156: 826-32.
19. Masuda D, Nakagawa-Toyama Y, Nakatani K, et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009; 39: 689-98.
20. Nozaki Y, Fujita K, Yoneda M, et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009; 51: 548-56.
21. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-61.
22. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 2003; 108: 2034-40.
23. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008; 266: 37-52.
24. Yamaoka-Tojo M, Ushio-Fukai M, Hilenski L, et al. IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species-dependent endothelial migration and proliferation. Circ Res 2004; 95: 276-83.
25. McCord JM. The evolution of free radicals and oxidative stress. Am J Med 2000; 108: 652-9.
26. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91: 7A-11.
27. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003; 24: 471-8.
28. Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc Res 2006; 71: 226-35.
29. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
30. El-Benna J, Dang PM, Gougerot-Pocidalo MA, Marie JC, Braut-Boucher F. p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases. Exp Mol Med 2009; 41: 217-25.
31. Fan LM, Teng L, Li JM. Knockout of p47phox uncovers a critical role of p40phox in reactive oxygen species production in microvascular endothelial cells. Arterioscler Thromb Vasc Biol 2009; 29: 1651-6.
32. Ushio-Fukai M, Alexander RW. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem 2004; 264: 85-97.
33. Harfouche R, Malak NA, Brandes RP, Karsan A, Irani K, Hussain SN. Roles of reactive oxygen species in angiopoietin-1/tie-2 receptor signaling. FASEB J 2005; 19: 1728-30.
34. Ushio-Fukai M. Vascular signaling through G protein-coupled receptors: new concepts. Curr Opin Nephrol Hypertens 2009; 18: 153-9.
35. Barry-Lane PA, Patterson C, van der Merwe M, et al. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 2001; 108: 1513-22.
36. Sorescu D, Weiss D, Lassegue B, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002; 105: 1429-35.
37. Vendrov AE, Hakim ZS, Madamanchi NR, Rojas M, Madamanchi C, Runge MS. Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells. Arterioscler Thromb Vasc Biol 2007; 27: 2714-21.
38. Freedman JE. Oxidative stress and platelets. Arterioscler Thromb Vasc Biol 2008; 28: s11-6.
39. Mowbray AL, Kang DH, Rhee SG, Kang SW, Jo H. Laminar shear stress up-regulates peroxiredoxins (PRX) in endothelial cells: PRX 1 as a mechanosensitive antioxidant. J Biol Chem 2008; 283: 1622-7.
40. Pronai L, Hiramatsu K, Saigusa Y, Nakazawa H. Atherosclerosis 199111; 90: 39-47.
41. Araujo FB, Barbosa DS, Hsin CY, Maranhao RC, Abdalla DS. Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis 1995; 117: 61-71.
42. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 2000; 28: 1815-26.
43. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-478.
44. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999; 85: 753-66.
45. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-62.
46. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109: IV6-19.
47. O'Donnell VB. Free radicals and lipid signaling in endothelial cells. Antioxid Redox Signal 2003; 5: 195-203.
48. Staprans I, Pan XM, Rapp JH, Grunfeld C, Feingold KR. Oxidized cholesterol in the diet accelerates the development of atherosclerosis in LDL receptor- and apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2000; 20: 708-14.
49. Staprans I, Pan XM, Rapp JH, Feingold KR. Oxidized cholesterol in the diet is a source of oxidized lipoproteins in human serum. J Lipid Res 2003; 44: 705-15.
50. Steinbrecher UP, Lougheed M, Kwan WC, Dirks M. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J Biol Chem 1989; 264: 15216-23.
51. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-92.
52. Mehta JL, Li D. Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. J Am Coll Cardiol 2002; 39: 1429-35.
53. Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholes-terolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 1998; 101: 1717-25.
54. Johnston TP, Zhou X. Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice results from an indirect effect. J Cardiovasc Pharmacol 2007; 49: 246-52.
55. Verhoye E, Langlois MR. Circulating oxidized low-density lipo-protein: a biomarker of atherosclerosis and cardiovascular risk? Clin Chem Lab Med 2009; 47: 128-37.
56. Matsuura E, Kobayashi K, Tabuchi M, Lopez LR. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res 2006; 45: 466-86.
57. Pillarisetti S, Paka L, Obunike JC, Berglund L, Goldberg IJ. Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest 1997; 100: 867-74.
58. Binder CJ, Silverman GJ. Natural antibodies and the autoimmunity of atherosclerosis. Springer Semin Immunopathol 2005; 26: 385-404.
59. Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001; 21: 844-8.
60. Holvoet P, Harris TB, Tracy RP, et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. Arterioscler Thromb Vasc Biol 2003; 23: 1444-8.
61. Rietzschel ER, Langlois M, De Buyzere ML, et al. Oxidized low-density lipoprotein cholesterol is associated with decreases in cardiac function independent of vascular alterations. Hypertension 2008; 52: 535-41.
62. Itabe H, Ueda M. Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J Atheroscler Thromb 2007; 14: 1-11.
63. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998; 98: 1487-94.
64. Holvoet P, Macy E, Landeloos M, et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem 2006; 52: 760-4.
65. Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 2006; 17: 502-9.
66. Tsimikas S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am J Cardiol 2006; 98: 9P-17.
67. Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized LDL: a bio-marker and a pathogenic factor. Curr Opin Lipidol 2009; 20: 363-9.
68. Ishigaki Y, Katagiri H, Gao J, et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 2008; 118: 75-83.
69. Mehta JL, Li DY, Chen HJ, Joseph J, Romeo F. Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun 2001; 289: 857-61.
70. Brand K, Banka CL, Mackman N, Terkeltaub RA, Fan ST, Curtiss LK. Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arterioscler Thromb 1994; 14: 790-7.
71. 2+ currents via lysophos-phatidylcholine-induced mitochondrial reactive oxygen species (ROS) production. Cardiovasc Res 2006; 69:855-64.
72. Zorn-Pauly K, Schaffer P, Pelzmann B, et al. Oxidized LDL induces ventricular myocyte damage and abnormal electrical activity-role of lipid hydroperoxides. Cardiovasc Res 2005; 66: 74-83.
73. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24: 729-41.
74. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1084-91.
75. Robinson JG, Ballantyne CM, Grundy SM, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin vs. atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol 2009; 103: 1694-702.
76. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943-8.
77. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1092-7.
78. Davidson MH, Ballantyne CM, Kerzner B, et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, pla-cebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004; 58: 746-55.
79. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholes-terolemia. J Am Coll Cardiol 2002; 40: 2125-34.
80. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004; 79: 620-9.
81. Feldman T, Koren M, Insull W Jr., et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration vs. simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004; 93: 1481-6.
82. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004; 93: 1487-94.
83. Sager PT, Melani L, Lipka L, et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003; 92: 1414-8.
84. Sager PT, Capece R, Lipka L, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 2005; 179: 361-7.
85. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hy-percholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-15.
86. Gonzalez-Ortiz M, Martinez-Abundis E, Kam-Ramos AM, Hernandez-Salazar E, Ramos-Zavala MG. Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc Drugs Ther 2006; 20: 143-6.
87. van Heek M, Austin TM, Farley C, Cook JA, Tetzloff GG, Davis HR. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes 2001; 50: 1330-5.
88. Deushi M, Nomura M, Kawakami A, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007; 581: 5664-70.
89. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 2008; 263: 256-73.
90. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-72.
91. Theilmeier G, De Geest B, Van Veldhoven PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/-mice. FASEB J 2000; 14: 2032-9.
92. Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001; 103: 108-12.
93. Tolle M, Pawlak A, Schuchardt M, et al. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008; 28: 1542-8.
94. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1: 16-9.
95. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-14.
96. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 1968; 9: 155-67.
97. Krieger M. Charting the fate of the good cholesterol: identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 1999; 68: 523-58.
98. Krieger M, Kozarsky K. Influence of the HDL receptor SR-BI on atherosclerosis. Curr Opin Lipidol 1999; 10: 491-7.
99. Rigotti A, Miettinen HE, Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev 2003; 24: 357-87.
100. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835-8.
101. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 2007; 18: 427-34.
102. Nakagami H, Osako MK, Takami Y, et al. Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis 2009; 203: 51-8.
103. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001; 23: 1209-30.
104. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000; 20: 189-97.
105. Schaefer EJ, Asztalos BF. The effects of statins on high-density lipoproteins. Curr Atheroscler Rep 2006; 8: 41-9.
106. Yamaoka-Tojo M, Tojo T, Kosugi R, et al. Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids Health Dis 2009; 8: 41.
107. Takahashi O, Glasziou PP, Perera R, et al. Lipid Re-screening: What Is the Best Measure and Interval? Heart 2009; 96: 448-52.
108. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994; 121: 641-7.
109. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294: 326-33.
110. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298: 776-85.
111. Lemieux I, Lamarche B, Couillard C, et al. Total cholesterol/HDL cholesterol ratio vs. LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med 2001; 161: 2685-92.
112. Goswami B, Rajappa M, Mallika V, Kumar S, Shukla DK. Apo-B/apo-AI ratio: a better discriminator of coronary artery disease risk than other conventional lipid ratios in Indian patients with acute myocardial infarction. Acta Cardiol 2008; 63: 749-55.
113. Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008; 117: 3002-9.
114. Davis HR, Jr., Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001; 21: 2032-8.
115. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005; 102: 8132-7.
116. Kuhlencordt PJ, Padmapriya P, Rutzel S, et al. Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. Atherosclerosis 2009; 202: 48-57.
117. Davies JP, Levy B, Ioannou YA. Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics 2000; 65: 137-45.
118. Altmann SW, Davis HR Jr., Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-4.
119. Wang J, Williams CM, Hegele RA. Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin Genet 2005; 67: 175-7.
120. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem 2005; 280: 12710-20.
121. Sane AT, Sinnett D, Delvin E, et al. Localization and role of NPC1L1 in cholesterol absorption in human intestine. J Lipid Res 2006; 47: 2112-20.
122. Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepatic neiman-pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 2009 [Epub ahead of print].
123. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.
124. Conde de la Rosa L, Schoemaker MH, Vrenken TE, et al. Superoxide anions and hydrogen peroxide induce hepatocyte death by different mechanisms: involvement of JNK and ERK MAP kinases. J Hepatol 2006; 44: 918-29.
125. Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006; 290: G583-9.
126. Yamagishi S, Nakamura K, Matsui T, Sato T, Takeuchi M. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Med Hypotheses 2006; 66: 844-6.
127. Hughes EA, Tracey I, Singhal S, Patel J. Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease. Med Hypotheses 2006; 67: 1463-4.
128. Zheng S, Hoos L, Cook J, et al. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 2008; 584: 118-24.
129. Hussein O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol 2008; 65: 637-45.
130. Nakamura T, Sato E, Fujiwara N, et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 2009; 60: 525-8.
131. Liu TZ, Stern A, Morrow JD. The isoprostanes: unique bioactive products of lipid peroxidation. An overview. J Biomed Sci 1998; 5: 415-20.
132. Esterbauer H. Estimation of peroxidative damage. A critical review. Pathol Biol (Paris) 1996; 44: 25-8.
133. Tsutsui T, Tsutamoto T, Wada A, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 2002; 39: 957-62.
134. Halliwell B. Why and how should we measure oxidative DNA damage in nutritional studies? How far have we come? Am J Clin Nutr 2000; 72: 1082-7.
135. Richter C. Oxidative damage to mitochondrial DNA and its relationship to ageing. Int J Biochem Cell Biol 1995; 27: 647-53.
136. Cesarone MR, Belcaro G, Carratelli M, et al. A simple test to monitor oxidative stress. Int Angiol 1999; 18: 127-30.
137. Cornelli U, Terranova R, Luca S, Cornelli M, Alberti A. Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr 2001; 131: 3208-11.
138. Neuman RB, Bloom HL, Shukrullah I, et al. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 2007; 53: 1652-7.
139. Zhao R, Ma X, Xie X, Shen GX. Involvement of NADPH oxidase in oxidized LDL-induced upregulation of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells. Am J Physiol Endocrinol Metab 2009; 297: E104-11.
140. Hayashi K, Nakamura S, Morishita R, et al. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther 2000; 7: 1664-71.
141. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008; 117: 2467-74.]
142. Celermajer DS. Reliable endothelial function testing: at our finger-tips? Circulation 2008; 117: 2428-30.
143. Bonetti PO, Pumper GM, Higano ST, Holmes DR, Jr., Kuvin JT, Lerman A. Non-invasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004; 44: 2137-41.
144. Settergren M, Bohm F, Ryden L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 2008; 29: 1753-60.
145. Han KH, Chang MK, Boullier A, et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving perox-isome proliferator-activated receptor gamma. J Clin Invest 2000; 106: 793-802.
146. Kleinhenz JM, Kleinhenz DJ, You S, et al. Disruption of endothelial peroxisome proliferator-activated receptor gamma (PPAR{gamma}) reduces vascular nitric oxide production. Am J Physiol Heart Circ Physiol 2009; 297: H1647-54.
147. Collins AR, Lyon CJ, Xia X, et al. Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res 2009; 104: e42-54.